Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
|Deserunt mollit sunt Lorem laborum do id aliqua dolore||08 Dec 2021||Lorem|
|Mitsubishi Tanabe Pharma’s ND0612 holds Phase III success uncertainty but its noninvasive delivery draws rescue therapy interest in Parkinson’s disease, even over oral approaches, experts say||20 Nov 2019||Shuan Sim|
|Akebia's vadadustat in CKD with anemia will focus on secondary endpoint values for future payer discussions- CEO||15 Jan 2018||Jennifer C. Smith-Parker|
|NeuroSense Therapeutics seeks CRO to help run Phase II ALS trial initiating in 3Q18 – CEO||22 Nov 2017||Christina Hwang|
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Insight on companies’ CRO and business development needs, strategies and relationships
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer